A randomized, double-blind, parallel-group, placebo-controlled, multinational clinical trial to evaluate the efficacy of aliskiren and valsartan versus placebo in lowering levels on NT-proBNP [N-terminal pro brain natriuretic peptide] in stabilized patients post acute coronary syndromes.

Trial Profile

A randomized, double-blind, parallel-group, placebo-controlled, multinational clinical trial to evaluate the efficacy of aliskiren and valsartan versus placebo in lowering levels on NT-proBNP [N-terminal pro brain natriuretic peptide] in stabilized patients post acute coronary syndromes.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Sep 2014

At a glance

  • Drugs Aliskiren (Primary) ; Valsartan
  • Indications Acute coronary syndromes; Heart failure
  • Focus Pharmacodynamics
  • Acronyms AVANTE-GARDE-TIMI 43
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Nov 2011 Pre-specified analysis assessing changes in aldosterone levels presented at the 84th Annual Scientific Sessions of the American Heart Association.
    • 17 Jun 2010 Primary endpoint 'Brain natriuretic peptide levels' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top